GLP1R and cardiovascular disorder: In conclusion, participants with underlying conditions like prediabetes and cardiovascular disease can use differing types of GLP-1 therapies that cater more toward prediabetic therapy and reduce the risk of cardiovascular disease, respectively (Table 1).